Current management of uterine sarcomas

Clinical and Translational Oncology

Volumn 13, Issue 5, 2011, Pages 307-314

  García Martínez, Elena ^a   Prefasi, Lucas Egea ^b   García Donas, Jesús ^c   Escolar Pérez, Pedro Pablo ^d   Pastor, Francisco ^b   González Martín, Antonio ^e  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO SANTA LUCÍA   (Spain)

^e MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Chemotherapy; Endometrial stroma sarcoma; Uterine carcinosarcoma; Uterine leyomisarcoma; Uterine sarcomas

Indexed keywords

AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GESTAGEN; GONADORELIN DERIVATIVE; IFOSFAMIDE; LETROZOLE; MEDROXYPROGESTERONE; MESNA; PACLITAXEL; PAZOPANIB; PLACEBO; RIDAFOROLIMUS; SUNITINIB; TEMOZOLOMIDE; TRABECTEDIN; VINCRISTINE; VINDESINE;

ABDOMINAL DISTENSION; ABDOMINAL HYSTERECTOMY; ADENOSARCOMA; ADVANCED CANCER; ANEMIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; DIFFERENTIAL DIAGNOSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; ENDOMETRIAL STROMAL TUMOR; ENDOMETRIUM BIOPSY; ENDOMETRIUM SARCOMA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEIOMYOSARCOMA; LUNG DISEASE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MITOSIS RATE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SALPINGOOOPHORECTOMY; SARCOMA; SOFT TISSUE SARCOMA; SURGICAL APPROACH; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR NECROSIS; UNDIFFERENTIATED STROMAL SARCOMA; UTERINE CARCINOSARCOMA; UTERUS SARCOMA; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LEIOMYOSARCOMA; MEDICAL ONCOLOGY; SARCOMA; SARCOMA, ENDOMETRIAL STROMAL; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 79960681004     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0659-0     Document Type: Review

References (57)

1. Prat J (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104:177-178
2. D'Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116:131-139
3. Abeler VM, Røyne O, Thoresen S et al (2009) Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54:355-364
4. Dionigi A, Oliva E, Clement PB, Young RH (2002) Endometrial stromal nodules and endometrial stromal tumors with limited infi ltration: a clinicopathologic study of 50 cases. Am J Surg Pathol 26:567-581 (Pubitemid 34438717)
5. Chang KL, Crabtree GS, Lim-Tan SK et al (1990) Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 14:415-438 (Pubitemid 20140662)
6. Baker P, Oliva E (2007) Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques. J Clin Pathol 60:235-243 (Pubitemid 46447736)
7. Kurihara S, Oda Y, Ohishi Y et al (2008) Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32: 1228-1238
8. Nucci MR, Harburger D, Koontz J et al (2007) Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fl uorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol 31:65-70 (Pubitemid 46036903)
9. Mansi JL, Ramachandra S, Wiltshaw E, Fisher C (1990) Endometrial stromal sarcomas. Gynecol Oncol 36:113-118 (Pubitemid 20038014)
10. Clement PB, Scully RE (1990) Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 21:363-381 (Pubitemid 20141021)
11. Soslow RA, Ali A, Oliva E (2008) Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol 32:1013-1021
12. Blom R, Guerrieri C (1999) Adenosarcoma of the uterus: a clinicopathologic, DNA fl ow cytometric, p53 and mdm-2 analysis of 11 cases. Int J Gynecol Cancer 9:37-43 (Pubitemid 29095788)
13. Ferguson SE, Tornos C, Hummer A et al (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31:1653-1661 (Pubitemid 350287563)
14. Soslow RA, Bissonnette JP, Wilton A et al (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31:979-987 (Pubitemid 47012293)
15. Bell SW, Kempson RL, Hendrickson MR (1994) Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pat hol 18: 535-558 (Pubitemid 24150803)
16. O'Neill CJ, McBride HA, Connolly LE, Mc-Cluggage WG (2007) Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50:851-858 (Pubitemid 46850073)
17. Akhan SE, Yavuz E, Tecer A et al (2005) The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 99:36-42 (Pubitemid 41354580)
18. Atkins KA, Arronte N, Darus CJ, Rice LW (2008) The use of p16 in enhancing the histologic classify cation of uterine smooth muscle tumors. Am J Surg Pathol 32:98-102
19. Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 93:204-208 (Pubitemid 38429571)
20. Bansal N, Herzog TJ, Burke W et al (2008) The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 110:43-48
21. Gadducci A, Cosio S, Romanini A, Genazzani AR (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65:129-142
22. Leath CA III, Huh WK, Hyde J Jr et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105:630-634 (Pubitemid 46734182)
23. Park JY, Kim DY, Suh DS et al (2008) Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol 134:1277-1287
24. Ayhan A, Aksan G, Gultekin M et al (2009) Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas. Arch Gynecol Obstet 280:79-85
25. Kapp DS, Shin JY, Chan JK (2008) Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112:820-830 (Pubitemid 351240576)
26. Leitao MM, Sonoda Y, Brennan MF et al (2003) Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91:209-212 (Pubitemid 37188613)
27. Riopel J, Plante M, Renaud MC et al (2005) Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol 96:402-406 (Pubitemid 40127141)
28. Chan JK, Kawar NM, Shin JY et al (2008) Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 99:1210-1215
29. Shah JP, Bryant CS, Kumar S et al (2008) Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 112:1102-1108
30. Odunsi K, Moneke V, Tammela J et al (2004) Effi cacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer 14:659-664 (Pubitemid 39062923)
31. Pautier P, Rey A, Haie-Meder C et al (2004) Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer 14:1112-1117 (Pubitemid 39603354)
32. Pautier P, Genestie C, Fizazi K et al (2002) Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer 12:749-754 (Pubitemid 35388045)
33. Omura GA, Blessing JA, Major F et al (1985) A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 3:1240-1245 (Pubitemid 15226529)
34. Hensley ML, Ishill N, Soslow R et al (2009) Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 112:563-567
35. Sampath S, Schultheiss TE, Ryu JK, Wong JY (2010) The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys 76:728-734
36. Reed NS, Mangioni C, Malmström H et al (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808-818
37. Ferrer F, Sabater S, Farrús B et al (1999) Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 44:47-52 (Pubitemid 29186187)
38. Wolfson AH, Brady MF, Rocereto T et al (2007) A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as postsurgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177-185 (Pubitemid 47575740)
39. Van GM, Verweij J, Judson I, Nielsen OS (2002) Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549 (Pubitemid 34185394)
40. Giuntoli RL, Garrett-Mayer E, Bristow RE, Gostout BS (2007) Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 106:82-88 (Pubitemid 46901078)
41. Amant F, Coosemans A, Debiec-Rychter M et al (2009) Clinical management of uterine sarcomas. Lancet Oncol 10:1188-1198
42. Look KY, Sandler A, Blessing JA et al (2004) Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92:644-647 (Pubitemid 38183157)
43. Hensley ML, Blessing JA, Mannel R, Rose PG (2008) Fixed-dose rate gemcitabine plus docetaxel as fi rst-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329-334 (Pubitemid 351754961)
44. Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824-2831 (Pubitemid 34651511)
45. Hensley ML (2010) Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol 22:356-361
46. Garcia del Muro X, Lopez-Pousa A, Martin J et al (2005) A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 104:1706-1712 (Pubitemid 41437435)
47. Anderson S, Aghajanian C (2005) Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 98: 99-103 (Pubitemid 40834271)
48. Ferriss JS, Atkins KA, Lachance JA et al (2010) Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer 20:120-125
49. Garcia-Carbonero R, Supko JG, Maki RG et al (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484-5492
50. Uchida T, Nakakawaji K, Sakamoto J et al (1996) The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg Today 26:138-141 (Pubitemid 26088328)
51. Hardman MP, Roman JJ, Burnett AF, Santin AD (2007) Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 110:518-520 (Pubitemid 47417749)
52. O'Cearbhaill R, Zhou Q, Iasonos A et al (2010) Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 116: 424-429
53. Kanjeekal S, Chambers A, Fung MF, Verma S (2005) Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 97:624-637 (Pubitemid 40614914)
54. Sutton G, Brunetto VL, Kilgore L et al (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 79:147-153
55. Homesley HD, Filiaci V, Markman M et al (2007) Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 25:526-531 (Pubitemid 350002959)
56. Powell MA, Filiaci VL, Rose PG et al (2010) Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 28:2727-2731
57. Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19:347-352 (Pubitemid 46883524)